AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00202163
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02163993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ
Trial: NCT01487096
Drug: Placebo (placebo for teriflunomide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablet~oral administration
Trial: NCT00017381
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00760864
Drug: TAK-715 and methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Trial: NCT00760864
Drug: TAK-715 and methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Trial: NCT00760864
Drug: TAK-715 and methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Trial: NCT00760864
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
Trial: NCT02808455
Drug: (Treatment A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 100-mg capsules of pacritinib administered as a single oral dose
Trial: NCT02808455
Drug: (Treatment B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 80-mg oral solution dose of pacritinib
Trial: NCT04050293
Drug: SPN-538
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive SPN-538
Trial: NCT04050293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Placebo
Trial: NCT02936557
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-054)
Trial: NCT03355079
Drug: SmofKabiven® E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
Trial: NCT01638923
Drug: EV/DNG (Qlaira, Natazia, BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
Trial: NCT01638923
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be taken orally daily for 7 cycles of 28 days each.
Trial: NCT00435370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05997004
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgical creation of umbilical port Control group received injection normal saline 1ml.
Trial: NCT01176903
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pressurized metered dose inhaler
Trial: NCT01808157
Drug: CT327 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01808157
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03848533
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)
Trial: NCT03848533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)
Trial: NCT00506961
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
Trial: NCT00506961
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
Trial: NCT01410448
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids were administered according to local clinical practice.
Trial: NCT04383912
Drug: Botox Injectable Product
RxNorm normalized name: Botox Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
Trial: NCT02186951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
Trial: NCT04730297
Drug: paracetamol 500 mg plus codeine 30 mg preoperative administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg
Trial: NCT04730297
Drug: ibuprofen 400 mg preoperative administration
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: each patient 30 minutes before surgery received ibuprofen 400 mg
Trial: NCT04730297
Drug: Placebo oral tablet preoperative administration
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: each patient 30 minutes before surgery received placebo
Trial: NCT00014378
Drug: Chinese Herb Huanglian (Coptis chinesis)
RxNorm normalized name: Coptis chinensis root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
Trial: NCT04762147
Drug: paracetamol, the group P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
Trial: NCT02939937
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
Trial: NCT02939937
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
Trial: NCT00985556
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT02571569
Drug: BAY1093884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
Trial: NCT02571569
Drug: BAY1093884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
Trial: NCT00756886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
Trial: NCT04131517
Drug: Microgynon 30®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
Trial: NCT02152592
Drug: PCM/Oxy1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled Release oxycodone 10 mg orally twice a day for 24 hours
Trial: NCT02152592
Drug: PCM/Oxy2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR oxycodone 10 mg orally twice a day for 48 hours
Trial: NCT00803010
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate: administered on day 1 at dose of 15 mg/m\^2, and a dose of 10 mg/m\^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
Trial: NCT04479917
Drug: TPN171H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
Trial: NCT04479917
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
Trial: NCT01453569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simulant of sodium oligo-mannurarate capsule
Trial: NCT00723411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected subcutaneously at days 1, 30, 90 and 270
Trial: NCT01153191
Drug: sub-q gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
Trial: NCT01495338
Drug: AC-170 0.17%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in one eye at one timepoint
Trial: NCT01495338
Drug: AC-170 0.24% (Formulation 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in one eye at one timepoint
Trial: NCT01490762
Drug: Technosphere Insulin Inhalation Powder using the Gen2C inhaler
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Powder
Trial: NCT01490762
Drug: Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT02909972
Drug: ALRN-6924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
Trial: NCT00681538
Drug: Sativex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
Trial: NCT00681538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Trial: NCT00630812
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
Trial: NCT04209777
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.
Trial: NCT00692510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral, dose once daily, 7 days
Trial: NCT00692510
Drug: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix
Trial: NCT01329029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03578874
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO
Trial: NCT00240318
Drug: Rosuvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00344123
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r..
Trial: NCT01218438
Drug: Immune Globulin Subcutaneous (Human), 20% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infusion with IGSC, 20%
Trial: NCT02786082
Drug: 20mg Azilsartan Tablets
RxNorm normalized name: azilsartan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength: 20mg, oral administration 1 tablet/ day
Trial: NCT02786082
Drug: 40mg Azilsartan Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength: 40mg, oral administration 1 tablet/ day
Trial: NCT01327326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 1 Time Dose
Trial: NCT00037635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Trial: NCT02918409
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00243412
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
Trial: NCT03653403
Drug: IDP-126 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Component A
Trial: NCT00678587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, once daily, oral
Trial: NCT00243412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
Trial: NCT02364167
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
Trial: NCT00275119
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03574935
Drug: External Chinese medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome.
Trial: NCT03574935
Drug: External Western medicine
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear).
Trial: NCT04729491
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500mg/day for 05 days
Trial: NCT04729491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
Trial: NCT02981277
Drug: Transcricoid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine delivery using Transcricoid Injection
Trial: NCT02981277
Drug: Spray as you go
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine delivery using Spray as you go method
Trial: NCT02671942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02860806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of matching placebo.
Trial: NCT00655980
Drug: Vitamin B12 and folic acid
RxNorm normalized name: VITAMIN B12 AND FOLIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
Trial: NCT01367262
Drug: LY2886721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03240393
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
Trial: NCT01606761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
Trial: NCT01606761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
Trial: NCT02497157
Drug: Continuous intravenous infusion of fluorouracil (CIV 5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02497157
Drug: Levofolinate calcium (l-LV)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02415439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00993421
Drug: LY377604
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given daily, orally for 24 weeks
Trial: NCT00993421
Drug: Placebo LY377604
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given daily, orally for 24 weeks
Trial: NCT02459574
Drug: Anti-Arrhythmic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed.
Trial: NCT02940626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01015482
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil Infusion
Trial: NCT05737173
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular knee injection
Trial: NCT02626572
Drug: S47445 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
Trial: NCT02626572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
Trial: NCT02038673
Drug: ASP5878
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00751855
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
Trial: NCT00751855
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00575952
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV